共 50 条
Recent pharmacological advances in the management of gout
被引:14
|作者:
Davies, Kristen
[1
]
Bukhari, Marwan A. S.
[1
,2
]
机构:
[1] Univ Lancaster, Fac Hlth & Med, Lancaster, England
[2] Univ Hosp Morecambe Bay NHS Fdn Trust, Royal Lancaster Infirm, Dept Rheumatol, Lancaster, England
关键词:
gout;
management;
EULAR;
IL-1;
allopurinol;
canakinumab;
anakinra;
febuxostat;
pharmacology;
lesinurad;
DOUBLE-BLIND;
TOPHACEOUS GOUT;
URIC-ACID;
LOWERING THERAPY;
COST-EFFECTIVENESS;
FLARE PREVENTION;
RENAL-FUNCTION;
PHASE-III;
ALLOPURINOL;
FEBUXOSTAT;
D O I:
10.1093/rheumatology/kex343
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Gout is the most common cause of inflammatory arthritis worldwide, and reports show that despite availability of therapies, management is still suboptimal. The new EULAR 2016 recommendations for the treatment of gout highlight the huge development in gout therapies, and the number of drugs being trialled only continues to increase. A clinical review of the evidence that underlies the recommendations from EULAR can reveal possible gaps in the literature and avenues for future research into gout therapies.
引用
收藏
页码:951 / 958
页数:8
相关论文